Evidence map›Paper›PMID 35702954›Full record

ArticleAnnals of clinical and translational neurology2022

Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms.

Jacqueline E Shanley, Andrew F Valenciano, Garrett Timmons, Annalise E Miner, Visesha Kakarla, Torge Rempe, Jennifer H Yang, Amanda Gooding, Marc A Norman, Sarah J Banks and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. A Step Forward in Long COVID Research: Validating the Post-COVID Cognitive Impairment Scale.European journal of investigation in health, psychology and education · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jacqueline E ShanleyDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.ORCID 0000-0002-5079-9223
Andrew F ValencianoDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Garrett TimmonsDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Annalise E MinerDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Visesha KakarlaDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Torge RempeDepartment of Neurology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Jennifer H YangDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Amanda GoodingDepartment of Psychiatry, University of California, San Diego, San Diego, California, USA.
Marc A NormanDepartment of Psychiatry, University of California, San Diego, San Diego, California, USA.
Sarah J BanksDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.
Michelle L RitterDepartment of Infectious Diseases, University of California, San Diego, San Diego, California, USA.
Ronald J EllisDepartment of Neurosciences and Psychiatry, University of California, San Diego, San Diego, California, USA.ORCID 0000-0003-4931-752X
Lucy HortonDepartment of Infectious Diseases, University of California, San Diego, San Diego, California, USA.
Jennifer S GravesDepartment of Neurosciences, University of California, San Diego, San Diego, California, USA.ORCID 0000-0003-1539-1940
University of San Diego · USUniversity of California San Diego · USUniversity of Florida · US

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

objectiveTo assess the initial features and evolution of neurologic Postacute Sequelae of SARS-CoV-2 infection (neuro-PASC) in patients with and without prior neurologic disease.

methodsParticipants with neurologic symptoms following acute SARS-CoV-2 infection were recruited from October 9, 2020 to October 11, 2021. Clinical data included a SARS-CoV-2 infection history, neurologic review of systems, neurologic exam, Montreal cognitive assessment (MoCA), and symptom-based self-reported surveys at baseline (conducted after acute infection) and 6-month follow-up assessments.

resultsFifty-six participants (69% female, mean age 50 years, 29% with prior neurologic disease such as multiple sclerosis) were enrolled, of which 27 had completed the 6-month follow-up visit in this ongoing study. SARS-CoV-2 infection severity was largely described as mild (39.3%) or moderate (42.9%). At baseline, following acute infection, the most common neurologic symptoms were fatigue (89.3%) and headaches (80.4%). At the 6-month follow-up, memory impairment (68.8%) and decreased concentration (61.5%) were the most prevalent, though on average all symptoms showed a reduction in reported severity score at the follow-up. Complete symptom resolution was reported in 33.3% of participants by 6 months. From baseline to 6 months, average MoCA scores improved overall though 26.3% of participants' scores decreased. A syndrome consisting of tremor, ataxia, and cognitive dysfunction (PASC-TAC) was observed in 7.1% of patients.

interpretationEarly in the neuro-PASC syndrome, fatigue and headache are the most commonly reported symptoms. At 6 months, memory impairment and decreased concentration were most prominent. Only one-third of participants had completed resolution of neuro-PASC at 6 months, although persistent symptoms trended toward improvement at follow-up.

Indexed as

SARS-CoV-2COVID-19Disease ProgressionFatigueFemaleHeadacheHumansLongitudinal StudiesMaleMemory DisordersMiddle AgedNervous System DiseasesCOVID-19postacute sequelae of COVID-19 infection

Identifiers

PMID35702954
PMCPMC9268882
OpenAlexW4282962692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.